P2RX5-TAX1BP3 (Gene)

Organism:

Homo sapiens

Gene:

P2RX5-TAX1BP3 associations

Synonyms:ENTREZ:100533970, HGNC:49191, NR_037928, P2RX5, P2RX5-TAX1BP3 readthrough (NMD candidate), P2RX5-TAX1BP3, P2X5

Id:ENSG00000257950

Entrez:100533970

Ensembl:ENSG00000257950

Description:P2RX5-TAX1BP3 readthrough (NMD candidate)

This locus represents naturally occurring read-through transcription between the neighboring P2RX5 (purinergic receptor P2X, ligand-gated ion channel, 5) and TAX1BP3 (Tax1 binding protein 3) genes on chromosome 17. The read-through transcript is a candidate for nonsense-mediated mRNA decay (NMD), and is thus unlikely to produce a protein product. [provided by RefSeq, Mar 2011]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View P2RX5-TAX1BP3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with P2RX5-TAX1BP3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using P2RX5-TAX1BP3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for P2RX5-TAX1BP3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with P2RX5-TAX1BP3.

Results found

Linked to

	Label	Description
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE147815 GSE147817 LSD1 inhibition McCoy 2 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE206226 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 7 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE223313 naringenin 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 XPO1 inhibition Dexamethasone 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE147815 GSE147817 LSD1 inhibition McCoy 2 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 2 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE206226 cisplatin 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE146982 metformin 7 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE100148 EZH2 inhibition 4 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE223313 naringenin 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE135350 XPO1 inhibition Dexamethasone 2 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.